UNSPSC 51373447: Codeine/menthol/pheniramine/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373447 Codeine/menthol/pheniramine/phenylephrine, a Commodity code, encompasses pharmaceutical and over-the-counter (OTC) products that state and local governments procure for public health, emergency response, and community health support. Recent solicitations show demand for naloxone kits, safe drug deactivation systems, and generic multi-source pharmaceuticals distributed through established wholesaler networks. Issuing bodies include county health departments, state purchasing cooperatives, and multistate purchasing alliances. Seminole County, Florida and the Minnesota Department of Administration represent the types of jurisdictions actively buying under this code — the former acquiring specific emergency-response medications, the latter coordinating pharmaceutical procurement across multiple state and local participants through a cooperative purchasing vehicle.

Activity under this code spans Florida and the upper Midwest, with Minnesota's multistate cooperative purchasing alliance (MMCAP) serving as a hub for broader regional and national participation including Oregon. Seminole County released an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and quarterly delivery to the Seminole County Community Health Building in Sanford. The Minnesota Department of Administration's Office of State Procurement issued a Request for Proposal (MMCAP S1070000015802) on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products; proposals were due March 26, 2026, with awarded vendors effective July 1, 2026. Both procurements require manufacturers or authorized distributors to comply with FDA requirements, cGMP standards, Drug Supply Chain Security Act (DSCSA) certification, and established insurance minimums; the MMCAP vehicle imposes a 3 percent administrative fee and performance penalties for late reporting or onboarding delays.